Cite

HARVARD Citation

    Ho, A. et al. (n.d.). 1046OPreliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Annals of oncology. p. . [Online]. 
  
Back to record